{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:41:38Z","timestamp":1790163698785,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"NCI","award":["5K23CA157631"],"award-info":[{"award-number":["5K23CA157631"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.ejca.2015.10.015","type":"journal-article","created":{"date-parts":[[2016,1,4]],"date-time":"2016-01-04T18:01:18Z","timestamp":1451930478000},"page":"163-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach"],"prefix":"10.1016","volume":"53","author":[{"given":"Mizuki","family":"Nishino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren K.","family":"Brais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichole V.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Hatabu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew H.","family":"Kulke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil H.","family":"Ramaiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2015.10.015_bib1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0033-8389(03)00109-X","article-title":"High-resolution CT of drug-induced lung disease","volume":"40","author":"Erasmus","year":"2002","journal-title":"Radiol Clin North Am"},{"key":"10.1016\/j.ejca.2015.10.015_bib2","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1634\/theoncologist.2015-0033","article-title":"Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy: radiographic pattern-based approach in Waldenstrom macroglobulinemia as a Paradigm","volume":"20","author":"Nishino","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2015.10.015_bib3","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJMc1505197","article-title":"Anti-PD-1-related pneumonitis during cancer immunotherapy","volume":"373","author":"Nishino","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ejca.2015.10.015_bib4","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","article-title":"Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab","volume":"3","author":"Tirumani","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ejca.2015.10.015_bib5","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1164\/ajrccm.165.2.ats01","article-title":"This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001","volume":"165","author":"American Thoracic Society\/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ejca.2015.10.015_bib6","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ejca.2015.10.015_bib7","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1200\/JCO.2009.24.0994","article-title":"Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia","volume":"28","author":"Ghobrial","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.10.015_bib8","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2015.10.015_bib9","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"issue":"Suppl. 2","key":"10.1016\/j.ejca.2015.10.015_bib10","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/CCO.0b013e32835de8ee","article-title":"Temsirolimus in the treatment of mantle cell lymphoma: frequency and management of adverse effects","volume":"25","author":"Bouabdallah","year":"2013","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ejca.2015.10.015_bib11","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/bju.12420","article-title":"Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes","volume":"113","author":"Atkinson","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.ejca.2015.10.015_bib12","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.ejca.2012.03.012","article-title":"Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome","volume":"48","author":"Dabydeen","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2015.10.015_bib13","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1200\/JCO.2010.29.2235","article-title":"Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus","volume":"29","author":"Maroto","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.10.015_bib14","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1093\/annonc\/mdp060","article-title":"Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors","volume":"20","author":"Soria","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2015.10.015_bib15","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2015.10.015_bib16","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2015.10.015_bib17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000351103","article-title":"Successful everolimus treatment in a patient with advanced pancreatic neuroendocrine tumor who developed everolimus-induced interstitial lung disease on two occasions: a case report","volume":"59","author":"Nakayama","year":"2013","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ejca.2015.10.015_bib18","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1186\/1756-0500-6-471","article-title":"Severe hypersensitivity pneumonitis associated with everolimus therapy for neuroendocrine tumour: a case report","volume":"6","author":"Sibertin-Blanc","year":"2013","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.ejca.2015.10.015_bib19","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.ejrad.2015.01.021","article-title":"Interstitial lung abnormalities in treatment-naive advanced non-small-cell lung cancer patients are associated with shorter survival","volume":"84","author":"Nishino","year":"2015","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.ejca.2015.10.015_bib20","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1634\/theoncologist.2014-0037","article-title":"Real-world study of everolimus in advanced progressive neuroendocrine tumors","volume":"19","author":"Panzuto","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2015.10.015_bib21","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.ejca.2006.03.015","article-title":"Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus","volume":"42","author":"Duran","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2015.10.015_bib22","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.2165\/00003495-200868110-00004","article-title":"Cigarette smoking and diffuse lung disease","volume":"68","author":"Patel","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.ejca.2015.10.015_bib23","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3346\/jkms.2012.27.4.450","article-title":"Temozolomide-associated bronchiolitis obliterans organizing pneumonia successfully treated with high-dose corticosteroid","volume":"27","author":"Kim","year":"2012","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.ejca.2015.10.015_bib24","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1183\/09031936.00065909","article-title":"Hypersensitivity pneumonitis associated with temozolomide","volume":"34","author":"Guilleminault","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ejca.2015.10.015_bib25","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1097\/CAD.0b013e328356f5b0","article-title":"Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review","volume":"23","author":"Dixit","year":"2012","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejca.2015.10.015_bib26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2174\/1574886308666140106154343","article-title":"A fatal case of acute interstitial pneumonia (AIP) in a woman affected by glioblastoma","volume":"9","author":"Balzarini","year":"2014","journal-title":"Curr Drug Saf"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915009296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915009296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T06:57:32Z","timestamp":1537081052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804915009296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":26,"alternative-id":["S0959804915009296"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2015.10.015","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2015.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}